Medical Oncology

, 36:85 | Cite as

Outcomes in patients ≥ 80 years with a diagnosis of a hepatopancreaticobiliary (HPB) malignancy

  • A. R. Lewis
  • C. Cipriano
  • X. Wang
  • R. Ward
  • A. Fitzpatrick
  • A. R. M. Scott
  • A. Rashed
  • H. Raja
  • A. Lamarca
  • R. A. Hubner
  • J. W. Valle
  • M. G. McNamaraEmail author
Original Paper


Older patients are underrepresented in oncological clinical trials. The incidence of hepatopancreaticobiliary (HPB) malignancies is higher in older patients, but data on outcomes are lacking. This study assessed patient outcomes in those < 80 and ≥ 80 years with a HPB malignancy seen at a tertiary referral centre, The Christie NHS Foundation Trust. Data on patients with a HPB malignancy were collected retrospectively between 2012 and 2017 via on-line case-note review. Survival was calculated using the Kaplan–Meier method and prognostic factors using log-rank analysis. Of 1421 patients, 10% were ≥ 80 years. Of patients < 80 and ≥ 80 years, 56% and 57% had pancreas cancer, 39% and 36% biliary tract cancer, and 5% and 7% had hepatocellular carcinoma, respectively. Amongst patients ≥ 80 years, 75% had an Eastern Cooperative Oncology Group performance status (ECOG PS) 0–2. Patients ≥ 80 years had higher rates of comorbidity; 28% received systemic anti-cancer therapy (SACT), compared with 62% of patients < 80 years. Best supportive care (BSC) was instituted in 44% of older patients, compared with 13% in those < 80 years. Of patients ≥ 80 years who received SACT, 82% received monotherapy. Median overall survival (OS) for patients receiving palliative SACT was 10.07 months (95% CI 8.89–11.08) and 10.10 months (95% CI 6.30–12.30) in patients < 80 and ≥ 80 years, respectively, p 0.41; ECOG PS (p < 0.001) was prognostic for OS in older patients but Adult Comorbidity Evaluation-27 comorbidity score (p = 0.07, when comparing groups of ACE score ≤ 1 and > 1) was not. Baseline factors were similar in both age cohorts, but more comorbidities were present in older patients. Older patients were less likely to receive SACT, but when they did, they had an equivalent benefit in OS to younger patients.


Elderly oncology Geriatric Hepatobiliary Cancer 


Author contributions

Initial manuscript preparation: LAR and CC. Study concepts and design: McMG, CC and LAR. Data Acquisition: LAR, CC, WR, FA, SA, RA, RH. Quality control of data and algorithms: MMG and LAR. Statistical analysis: WX. Data Analysis and interpretation: WX, LAR, CC, MMG. Manuscript editing: All authors. Manuscript review: LAR, CC, WX, WR, FA, SARM, RA, RH, LA, HRA, VJW, MMG.

Compliance with ethical standards

Conflict of interest

Angela Lamarca received funding from ASCO Conquer Cancer Foundation Young Investigator Award and The Christie Charity. All authors declare no conflict of interest.

Ethical approval

This retrospective study was carried out in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Clinical Audit Committee of The Christie NHS Foundation Trust (reference 17/1923).


  1. 1.
    Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22:4626–31.CrossRefPubMedGoogle Scholar
  2. 2.
    Williams GR, Mackenzie A, Magnuson A, et al. Comorbidity in older adults with cancer. J Geriatr Oncol. 2016;7:249–57.CrossRefGoogle Scholar
  3. 3.
    Brunot A, Le Sourd S, Pracht M, Edeline J. Hepatocellular carcinoma in elderly patients: challenges and solutions. J Hepatocell Carcinoma. 2016;3:9–18.CrossRefPubMedGoogle Scholar
  4. 4.
    Borzio M, Dionigi E, Parisi G, Raguzzi I, Sacco R. Management of hepatocellular carcinoma in the elderly. World J Hepatol. 2015;7:1521–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Wildiers H, Heeren P, Extermann M, et al. International Society of Geriatric Oncology Consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32(24):2595–603.CrossRefPubMedGoogle Scholar
  6. 6.
    Miyamoto DT, Mamon HJ, Ryan DP, et al. Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or older. Int J Radiat Oncol Biol Phys. 2010;77:1171–7.CrossRefGoogle Scholar
  7. 7.
    Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer. 2013;4:635–43.CrossRefPubMedGoogle Scholar
  8. 8.
    Aduen JF, Sujay B, Dickson RC, et al. Outcomes after liver transplant in patients aged 70 years or older compared with those younger than 60 years. Mayo Clin Proc. 2009;84:973–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Takahashi H, Mizuta T, Kawazoe S, et al. Efficacy and safety of radiofrequency ablation for elderly hepatocellular carcinoma patients. Hepatol Res. 2010;40:997–1005.CrossRefGoogle Scholar
  10. 10.
    Edeline J, Crouzet L, Le Sourd S, et al. Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. Cancer Chemother Pharmacol. 2015;75:215–9.CrossRefGoogle Scholar
  11. 11.
    Wang P, Meng ZQ, Chen Z, et al. Survival rate of pancreatic cancer in elderly patients. Hepatogastroenterology. 2008;55:681–6.Google Scholar
  12. 12.
    van der Geest LG, Besselink MG, van Gestel YR, et al. Pancreatic cancer surgery in elderly patients: balancing between short-term harm and long-term benefit. A population-based study in the Netherlands. Acta Oncol. 2016;55:278–85.CrossRefGoogle Scholar
  13. 13.
    Green MR. Gemcitabine safety overview. Semin Oncol. 1996;23:32–5.Google Scholar
  14. 14.
    Vitale A, Spolverato G, Bagante F, et al. A multi-institutional analysis of elderly patients undergoing a liver resection for intrahepatic cholangiocarcinoma. J Surg Oncol. 2016;113:420–6.CrossRefGoogle Scholar
  15. 15.
    McNamara MG, Bridgewater J, Lopes A, et al. Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. BMC Cancer. 2017;17:262.CrossRefPubMedGoogle Scholar
  16. 16.
    Hurria A, Levit LA, Dale W, et al. Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement. J Clin Oncol. 2015;33:3826–33.CrossRefPubMedGoogle Scholar
  17. 17.
    Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011–24.CrossRefPubMedGoogle Scholar
  18. 18.
    Hentic O, Dreyer C, Rebours V, et al. Gemcitabine in elderly patients with advanced pancreatic cancer. World J Gastroenterol. 2011;17:3497–502.CrossRefPubMedGoogle Scholar
  19. 19.
  20. 20.
    Kallogjeri D, Gaynor SM, Piccirillo ML, et al. Comparison of comorbidity collection methods. J Am Coll Surg. 2014;219(2):245–55.CrossRefPubMedGoogle Scholar
  21. 21.
    Parmar AD, Vargas GM, Tamirisa NP, Sheffield KM, Riall TS. Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma. Surgery. 2014;156:280–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMedGoogle Scholar
  23. 23.
    Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. JCO. 1997;15:2403–13.CrossRefGoogle Scholar
  24. 24.
    Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.CrossRefPubMedGoogle Scholar
  25. 25.
    Bridgewater J, Lopes A, Palmer D, et al. Quality of life, long-term survivors and long-term outcome from the ABC-02 study. Br J Cancer. 2016;114:965–71.CrossRefPubMedGoogle Scholar
  26. 26.
    Horgan A, Knox J, Aneja P, Le L, McKeever E, McNamara M. Patterns of care and treatment outcomes in older patients with biliary tract cancer. Oncotarget. 2015;6:44995–5004.CrossRefPubMedGoogle Scholar
  27. 27.
    Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002;20:494–502.CrossRefGoogle Scholar
  28. 28.
    Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–65.CrossRefPubMedGoogle Scholar
  29. 29.
    Decoster L, Van Puyvelde K, Extermann M, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol. 2014;26(2):288–300.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • A. R. Lewis
    • 1
  • C. Cipriano
    • 2
  • X. Wang
    • 1
  • R. Ward
    • 1
  • A. Fitzpatrick
    • 1
  • A. R. M. Scott
    • 1
  • A. Rashed
    • 1
  • H. Raja
    • 1
  • A. Lamarca
    • 1
  • R. A. Hubner
    • 1
  • J. W. Valle
    • 1
    • 3
  • M. G. McNamara
    • 1
    • 3
    • 4
    Email author
  1. 1.The Christie NHS Foundation TrustManchesterUK
  2. 2.University of Manchester Medical SchoolManchesterUK
  3. 3.Division of Cancer SciencesUniversity of ManchesterManchesterUK
  4. 4.Department of Medical Oncology/Division of Cancer SciencesThe Christie NHS Foundation Trust/University of ManchesterManchesterUK

Personalised recommendations